Dept. of Physiology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, USA.
Am J Physiol Renal Physiol. 2011 Dec;301(6):F1195-201. doi: 10.1152/ajprenal.00339.2011. Epub 2011 Aug 24.
Renin expression in principal cells of collecting ducts (CD) is upregulated in angiotensin II (ANG II)-dependent hypertensive rats; however, it remains unclear whether increased CD-derived renin undergoes tubular secretion. Accordingly, urinary levels of renin (uRen), angiotensinogen (uAGT), and ANG II (uANG II) were measured in chronic ANG II-infused Sprague-Dawley rats (80 ng/min for 14 days, n = 10) and sham-operated rats (n = 10). Systolic blood pressure increased in the ANG II rats by day 5 and continued to increase throughout the study (day 13; ANG II: 175 ± 10 vs. sham: 116 ± 2 mmHg; P < 0.05). ANG II infusion increased renal cortical and medullary ANG II levels (cortical ANG II: 606 ± 72 vs. 247 ± 43 fmol/g; P < 0.05; medullary ANG II: 2,066 ± 116 vs. 646 ± 36 fmol/g; P < 0.05). Although plasma renin activity (PRA) was suppressed in the ANG II-infused rats (0.3 ± 0.2 vs. 5.5 ± 1.8 ng ANG I·ml(-1)·h(-1); P < 0.05), renin content in renal medulla was increased (12,605 ± 1,343 vs. 7,956 ± 765 ng ANG I·h(-1)·mg(-1); P < 0.05). Excretion of uAGT and uANG II increased in the ANG II rats [uAGT: 1,107 ± 106 vs. 60 ± 26 ng/day; P < 0.0001; uANG II: 3,813 ± 431 vs. 2,080 ± 361 fmol/day; P < 0.05]. By day 13, despite suppression of PRA, urinary prorenin content increased in ANG II rats [15.7 ± 3 vs. 2.6 ± 1 × 10(-3) enzyme units excreted (EUE)/day, P < 0.01] as was the excretion rate of renin (8.6 ± 2 × 10(-6) EUE/day) compared with sham (2.8 ± 1 × 10(-6) EUE/day; P < 0.05). Urinary renin and prorenin protein levels examined by Western blot were augmented ∼10-fold in the ANG II-infused rats. Concomitant AT(1) receptor blockade with candesartan prevented the increase. Thus, in ANG II-dependent hypertensive rats with marked PRA suppression, increased urinary levels of renin and prorenin reflect their augmented secretion by CD cells into the luminal fluid. The greater availability of renin and AGT in the urine reflects the capability for intratubular ANG II formation which stimulates sodium reabsorption in distal nephron segments.
在血管紧张素 II(ANG II)依赖性高血压大鼠中,主细胞中的肾素表达上调;然而,目前尚不清楚是否增加的 CD 衍生肾素经历管状分泌。因此,在慢性 ANG II 输注的 Sprague-Dawley 大鼠(80ng/min 持续 14 天,n=10)和假手术大鼠(n=10)中测量了尿肾素(uRen)、血管紧张素原(uAGT)和 ANG II(uANG II)的水平。ANG II 大鼠的收缩压在第 5 天升高,并在整个研究期间持续升高(第 13 天;ANG II:175±10 与 sham:116±2mmHg;P<0.05)。ANG II 输注增加了皮质和髓质 ANG II 水平(皮质 ANG II:606±72 与 247±43fmol/g;P<0.05;髓质 ANG II:2066±116 与 646±36fmol/g;P<0.05)。尽管 ANG II 输注大鼠的血浆肾素活性(PRA)受到抑制(0.3±0.2 与 5.5±1.8ng ANG I·ml(-1)·h(-1);P<0.05),但肾髓质中的肾素含量增加(12605±1343 与 7956±765ng ANG I·h(-1)·mg(-1);P<0.05)。ANG II 大鼠的 uAGT 和 uANG II 排泄增加[uAGT:1107±106 与 60±26ng/天;P<0.0001;uANG II:3813±431 与 2080±361fmol/天;P<0.05]。到第 13 天,尽管 PRA 受到抑制,ANG II 大鼠的尿前肾素含量增加[15.7±3 与 2.6±1×10(-3)酶单位排泄(EUE)/天,P<0.01],肾素排泄率也增加(8.6±2×10(-6)EUE/天)与 sham 相比(2.8±1×10(-6)EUE/天;P<0.05)。用 Western blot 检测的尿肾素和前肾素蛋白水平在 ANG II 输注大鼠中增加了约 10 倍。同时用坎地沙坦阻断 AT(1)受体可预防这种增加。因此,在具有明显 PRA 抑制的 ANG II 依赖性高血压大鼠中,尿肾素和前肾素水平的升高反映了它们由 CD 细胞分泌到管腔液体中的增加。尿中肾素和 AGT 的可用性增加反映了形成管内 ANG II 的能力,这刺激了远端肾单位的钠重吸收。